scholarly journals PCV65 Clinico-Economic Evaluation of Complex Cardiovascular Therapy with Magnesium Orotate in Patients with Chronic Heart Failure Versus Standard Therapy in Ukraine

2011 ◽  
Vol 14 (7) ◽  
pp. A376
Author(s):  
L. Iakovlieva ◽  
O. Kyrychenko ◽  
O. Mishchenko
Author(s):  
Andrija S. Grustam ◽  
Johan L. Severens ◽  
Jan van Nijnatten ◽  
Ron Koymans ◽  
Hubertus J. M. Vrijhoef

Objectives: Evidence exists that telehealth interventions (e.g., telemonitoring, telediagnostics, telephone care) in disease management for chronic heart failure patients can improve medical outcomes, and we aim to give an overview of the cost-effectiveness of these interventions.Methods: Based on the literature search on “heart failure” in combination with “cost” and “telehealth” we selected 301 titles and abstracts. Titles and abstracts were screened for a set of inclusion criteria: telehealth intervention, heart failure as the main disease, economic analysis present and a primary study performed. In the end, thirty-two studies were included for full reading, data extraction, and critical appraisal of the economic evaluation.Results: Most studies did not present a comprehensive economic evaluation, consisting of the comparison of both costs and effects between telehealth intervention and a comparator. Data on telehealth investment costs were lacking in many studies. The few studies that assessed costs and consequences comprehensively showed that telehealth interventions are cost saving with slight improvement in effectiveness, or comparably effective with similar cost to usual care. However, the methodological quality of the studies was in general considered to be low.Conclusions: The cost-effectiveness of telehealth in chronic heart failure is hardly ascertained in peer reviewed literature, the quality of evidence is poor and there was a difficulty in capturing all of the consequences/effects of telehealth intervention. We believe that without full economic analyses the cost-effectiveness of telehealth interventions in chronic heart failure remains unknown.


2019 ◽  
Vol 91 (3) ◽  
pp. 36-41 ◽  
Author(s):  
A V Budnevsky ◽  
A D Shurupova ◽  
A Ya Kravchenko ◽  
R E Tokmachev

The aim of the study was to evaluate the ARVI prevention effectiveness in patients with chronic heart failure (CHF) using interferon inducer amixin. Materials and methods. Conducted a comprehensive survey, dynamic monitoring and treatment of 60 patients aged from 49 to 70 years (mean age 60.25±4.57 years, 17 men and 43 women) with CHF with preserved ejection fraction of left ventricle (LVEF) (≥50%), II-III functional class (FC) according to the classification of new York Heart Association (NYHA), which developed as a result of coronary heart disease (CHD), hypertensive disease (HD). Of these, 30 patients (group 1) on the background of standard therapy for CHF received for the prevention of ARVI tiloron (Amixin) at a dose of 125 mg once a week for 6 weeks, two courses for 1 year. Group 2 patients received only standard therapy for CHF. Results. A decrease in the frequency of ARVI in patients with CHF treated with Amixin was found, which was accompanied by a decrease in the severity of subclinical inflammation by reducing the production of proinflammatory (IL-1β) and increasing the production of anti-inflammatory (IL-10) cytokines, reducing neurohumoral activation (reducing levels of aldosterone and Nt-proBNP), increasing the level of α- and γ-interferon. The positive dynamics of biomarkers of systemic inflammation and neurohormonal activation explains the improvement of the clinical course in patients with CHF (increase of tolerance to physical loads, reducing the number of visits to General practitioner and hospital admissions in the hospital during 12 months of observation). Conclusion. A promising approach to the prevention of SARS in patients with CHF is course therapy with Amixin (2 times a year before the seasonal rising in the incidence of respiratory viral infections and influenza), which allows to achieve both decreasing in the frequency of SARS per year, and improvement the clinical course of CHF.


2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Georgia Kourlaba ◽  
John Parissis ◽  
Apostolos Karavidas ◽  
Alexandra Beletsi ◽  
Charalambos Milonas ◽  
...  

2016 ◽  
Vol 36 (1) ◽  
pp. 12-19 ◽  
Author(s):  
Mónica Rincón ◽  
Maria Ximena Rojas ◽  
Viviana Alejandra Rodriguez Romero ◽  
Diana Carolina Tamayo ◽  
Camilo Franco ◽  
...  

2006 ◽  
Vol 9 (1-4) ◽  
pp. 121-131 ◽  
Author(s):  
Cornelis Boersma ◽  
Jasmina I Radeva ◽  
Marc A Koopmanschap ◽  
Adriaan A Voors ◽  
Maarten J Postma

1970 ◽  
Vol 1 (2) ◽  
pp. 207-215
Author(s):  
A Jahan ◽  
SM Ureevna ◽  
SE Vladimirovich

Background: In the pathogenesis of CHF neurohormonal changes, in particular, changes of activity of sympathetic nervous system (SNS) occupies an important position. For this reason, researchers concentrated on the use β-blockers in therapy of patients with CHF. They reduce heart rate, improve diastolic function of the myocardium, reduce secretion of renin and restore the sensitivity of β- adrenoreceptors to its regulatory influences. We studied the influence of the 3<sup>rd</sup>generation betaadrenoblocker – Carvedilol in patients with CHF- including clinical efficacy and reduction of oxidative stress. Methods: The study was conducted in Saint-Petersburg State Medical University, from January 2000 to June 2000. 37 patients (33 male and 4 female) with CHF class III or IV despite receiving standard therapy of heart failure were enrolled in the study for the treatment with Carvedilol. All of the patients received Carvedilol for 6 months at a dose of 12.5-50mg/day with standard therapy of Heart Failure, which was not changed during next 6 months. Results: The average age of the patients was 56.8±2.3 years. The cause of CHF was IHD. 34 patients had chronic stable angina (CCS class II-IV). The majority of the patients had a history of myocardial infarction (91.8%); of these 73.5% of the patients had a history of repeated MI. Hypertension stage 2 and 3 was associated in 32.4% patients.Long-term therapy with Carvedilol led to improvement of the clinical status of the patients. After 6 months therapy with Carvedilol frequency of hospitalization was significantly reduced (1.36±0.23 vs. 0.33±0.1; p<0,01). The patients were symptomatically improved after 6 months therapy with Carvedilol. There was a tendency of reduction of LV mass by 12.1% (214.0±11.1 gm/m<sup>2</sup> vs. 188.1±10.8 gm/m<sup>2</sup>, p<0.05). After treatment with Carvedilol there was significant increase in LVEF by 10% (30.0±1.5% to 33.0±0.1%; p<0.01) and increase in fractional shortening of LV by 22.2% (from 17.25±1.14 vs. 21.09±1.25; p<0.01). There was a significant reduction in plasma MDA, indicator of oxidative stress, in comparison with the baseline data. Conclusion: Carvedilol therapy in patients with Chronic heart failure improves clinical symptoms of patients with improvement in systolic & diastolic function of LV. Carvedilol also reduces oxidative stress in patients with heart failure. Keywords: Carvedilol, Heart failure, Ischaemic heart disease DOI: http://dx.doi.org/10.3329/cardio.v1i2.8240 Cardiovasc. j. 2009; 1(2): 207-215


Sign in / Sign up

Export Citation Format

Share Document